Why

Propion’s founders started their company because they believe that targeting the axis between the Propion Molecules™ and the rest of the body could address a significant portion of what causes us to age. Consumers are asking themselves what they can do to feel youthful in their later years and whether there are products they can take to push back against the effects of time – they are also increasingly relying on thought leaders to guide them. However, the public has gravitated towards celebrity scientists known better for their social media presence than their genuine research acumen. Specialist insight with the depth of knowledge to parse out what truly is and isn’t a breakthrough is lacking in the public conversation. That is perhaps why few, if any molecules presently marketed for their longevity promoting properties have achieved conclusive evidence about their benefit spanning the entirety of the human adult lifespan. Still, millions of health enthusiasts take what’s available because they are compelled by anxiety to do everything imaginable for their health. Hence, the meta-problem the company is trying to solve is the lack of consumer products whichaccomplish the goal of fundamentally slowing the body’s rate of aging.

Who

Founders

avtar image

Dr. Daniel Winer

Chairman & Scientific Director

“Much of this is new research and constitutes a fundamental discovery on how we could change aging.”

AWARDS

  • Top 10 Breakthroughs of the Decade (2005-2015)
  • Amgen Early Investor Award
  • Canada Research Chair

REVIEWER

  • Nature Metabolism
  • Nature Medicine
  • Cell Host and Microbe
avtar image

Nicholas Tubach

President & CEO

“We didn’t want to start a consumer product company, but we had to. The science is simply too compelling to not share with the world.”

B.A., Interdisciplinary Studies (Cell Biology and Entrepreneurship), UC Berkeley

Extended Team

Dr. Jan Scicinski

Head of Medicinal Chemistry

Scicinski is a drug discovery and development scientist, executive, and problem solver with a track record in new pharmaceutical product discovery and development. He has more than 35 years’ experience in the pharmaceutical and biotech industries, in both start-up and large corporate environments (GSK, Nuada, ALZA, EpicentRx), providing leadership for programs in drug discovery from hit identification to lead selection and for development projects including CMC, IND-enabling activities, clinical trial operations and regulatory filings and communication. Dr. Scicinski is a Fellow of the Royal Society of Chemistry with Chartered Chemist Status and holds a PhD from CambridgeUniversity and BSc hons from Imperial College, London. He has co-authored over 170 peer-reviewed publications, patents, abstracts and book chapters.

Dr. Burkhard Poeggeler

Product Specialist

Dr. Burkhard Poeggeler has been affiliated with the Georg-August-University Göttingen in Germany for more than 30 years and works on the biochemistry and pharmacology of prosurvival signaling. One focus of his research is using a holistic nutritive healthcare approach to aging. Over 100 Pubmed listed publications demonstrate his research on bioenergetic agents. Formerly the founder of a startup which tried to fund research on indole-3-propionic acid (Propion 1™) as a therapeutic for Alzheimer’s disease, Poeggeler helped to discover Propion 1™ and related compounds. He is the author of a textbook on the amino acid tryptophan and its metabolism.

Dr. Amine Zorgani

Board Member

Zorgani is an internationally sought after scientist, speaker, and advisor with a background in product development and a specialized social media following for his expertise in microbiology. He advises Propion on product design, product validation, and social networking.

Dr. Bill Andrews

Board Member

Andrews’ career can partially be measured in the millions of lives he has saved and improved by coinventing blockbuster drugs such as tissue plasminogen activator, beta-seron, and recombinant human growth hormone. He also led the team which discovered the human telomerase enzyme and has spoken at over 100 conferences about his research on telomeres.